Skip to content

Sleep Disorders and the Onset and Progression of ALS

Effect of Sleep Disorder on Onset and Progression of Amyotrophic Lateral Sclerosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04952038
Enrollment
200
Registered
2021-07-07
Start date
2020-08-01
Completion date
2022-03-31
Last updated
2021-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Brief summary

200 cases of ALS patients were collected to explore whether sleep disorders are related to earlier onset age, and whether sleep disorders accelerate the progress of ALS and shorten the survival time of ALS patients.

Detailed description

200 patients with ALS were collected. 1) sleep disorders were assessed by Pittsburgh sleep quality index (PSQI) and Epworth Sleepiness Scale (epworth) at baseline Sleeping Scale,ESS); 2) Name, age, gender and onset site were collected to explore whether sleep disorders were associated with earlier onset age; 3) The patients' function (ALSFRS-R) at baseline and every 3 months within 2 years were collected, and the end-point time (death and invasive breathing) was recorded to evaluate whether sleep disturbance accelerated the decline of patients' function and shortened their short-term survival.

Interventions

BEHAVIORALsleep disorder

ALS patients with or without sleep disorder

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients who have been diagnosed in the Department of Neurology of the Third Hospital of Beijing Medical University since August 2020. The clinical diagnosis of patients with amyotrophic lateral sclerosis includes: probable and define; * Informed consent has been signed.

Exclusion criteria

* Those who can not cooperate to complete the scale and receive follow-up.

Design outcomes

Primary

MeasureTime frameDescription
ALSFERS-R2 yearsALS functional score
end point event2 yearsdeath or invasive breathing

Countries

China

Contacts

Primary ContactDongsheng Fan
dsfan@sina.com+86 13701023871

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026